The results of clinical trials of SaNOtize's Nitric Oxide Nasal Spray (NONS) claimes an antiviral treatment against the coronavirus transmission. The Biotech company SaNOtize, UK has announced the results and said that the NONS not only prevents the transmission but also shortens the course of the novel coronavirus and reduces its severity.
Who is Making the Nasal Spray Vaccine:
Biotech Company SaNOtize, Vancouver has developed this Nitric Oxide Nasal Spray (NONS). Patients have to spray the nasal spray into the nose by themselves and this spray would reduce the value of the virus inside the nose. As the spray is inhaled through the nose neither the virus would grow nor it would infect the lungs.
Clinical trials for nasal spray have done in Canada and UK. In phase-2 of the trial, the viral load was reduced by 95% in 24 hours and 99% in 48 hours. This nasal spray has also proved effective against the UK variant of coronavirus.
Also Read: Queen’s 95th birthday won’t be a public celebration this year
Will this nasal spray come to India?
Dr. Gilli Regev, CEO and Managing Director of SaNOtize says that "we are looking for the partners in India and I hope this nasal spray will be successful in India too. I am in contact with big pharmaceutical companies in India." "We are expecting that phase 3 of clinical trials may occur in India, we are looking for funding", Dr. Regev added.
SaNOtize has not contacted the government and regulators.
Status of the nasal vaccine in India:
The Bharat Biotech, which developed covaxin, has started trials for its nasal vaccine 'Coroflu' in January.
In 2020, the chairman and managing director of India's Premiere Vaccine development center, Bharat Biotech International Limited told that the efforts are made to develop an intramuscular vaccine, but he really wanted to make an intranasal vaccine, which would be easy to administer like 'polio drops'.
However, a year later the vision of the nasal vaccine for coronavirus is near to reality, and the clinical trials and on their way. Dr. Ella Krishan's Bharat Biotech Institute has started the process of clinical trials for the nasal vaccine in its four centers in India - Nagpur, Hyderabad, Patna, and Chennai for their new Nasal vaccine for COVID-19.
The second wave of coronavirus has caused outrage across the country. The number of active positive cases is increasing day by day. On Wednesday, India reported 2.95 lakh cases and India has reached at top of the world in terms of deaths.